Reduced-dose (two-thirds) R-CHOP chemotherapy for elderly patients with non-Hodgkin lymphoma

被引：9

作者：

Kikuchi, Misato ^{[1
]}

Nakasone, Hideki ^{[1
]}

Akahoshi, Yu ^{[1
]}

Nakano, Hirofumi ^{[1
]}

Ugai, Tomotaka ^{[1
]}

Wada, Hidenori ^{[1
]}

Yamasaki, Ryoko ^{[1
]}

Sakamoto, Kana ^{[1
]}

Kawamura, Koji ^{[1
]}

Ishihara, Yuko ^{[1
]}

Sato, Miki ^{[1
]}

Ashizawa, Masahiro ^{[1
]}

Terasako-Saito, Kiriko ^{[1
]}

Kimura, Shun-ichi ^{[1
]}

Yamazaki, Rie ^{[1
]}

Kako, Shinichi ^{[1
]}

Kanda, Junya ^{[1
]}

Nishida, Junji ^{[1
]}

Sekiguchi, Naohiro ^{[2
]}

Noto, Satoshi ^{[2
]}

Kida, Michiko ^{[3
]}

Hangaishi, Akira ^{[3
]}

Usuki, Kensuke ^{[3
]}

Kanda, Yoshinobu ^{[1
]}

机构：

[1] Jichi Med Univ, Div Hematol, Saitama Med Ctr, Saitama 3308503, Japan

[2] Natl Hosp Org Disaster Med Ctr, Dept Hematol, Tokyo, Japan

[3] NTT Kanto Med Ctr, Div Hematol, Shinagawa, Tokyo, Japan

来源：

JOURNAL OF CHEMOTHERAPY | 2015年 / 27卷 / 02期

关键词：

Rituximab; Non-Hodgkin lymphoma; Diffuse large B-cell lymphoma; Relative dose intensity; Neutropenia; Elderly patients; R-CHOP; B-CELL LYMPHOMA; PATIENTS OLDER; RITUXIMAB; TRIAL; CYCLOPHOSPHAMIDE; VINCRISTINE; DOXORUBICIN; PREDNISONE;

D O I：

10.1179/1973947814Y.0000000219

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Elderly patients with non-Hodgkin lymphoma (NHL) have a poor prognosis. Owing to treatment-related toxicities, there is no standard chemotherapy for the elderly patients, especially those aged 70 years or older. In this study, we retrospectively evaluated the efficacy and toxicity of reduced-dose (two-thirds) R-CHOP chemotherapy as an initial chemotherapy for 45 patients aged 70 years or older with B-cell NHL. The WHO classification of NHL included diffuse large B-cell lymphoma (DLBCL) (31), mantle cell lymphoma (5), follicular lymphoma (4), extranodal marginal zone lymphoma (1), Burkitt lymphoma (1), and B-cell lymphoma whose further types were unclassified (3). The incidences of grade 4 neutropenia and febrile neutropenia (FN) were 51.1 and 15.6%, respectively. Efficacy was evaluated in patients with DLBCL. The overall and complete response (CR) rates were 96.7 and 90.0%, respectively. Two-year event-free survival (EFS) and overall survival (OS) were 84.4 and 89.2%, respectively. There was no treatment-related mortality. In conclusion, two-thirds R-CHOP chemotherapy is a promising treatment for elderly patients with B-cell NHL in terms of its efficacy and toxicity.

引用

页码：99 / 105

页数：7

共 16 条

[1] Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E-IPI) [J].

Advani, Ranjana H. ;

Chen, Haiyan ;

Habermann, Thomas M. ;

Morrison, Vicki A. ;

Weller, Edie A. ;

Fisher, Richard I. ;

Peterson, Bruce A. ;

Gascoyne, Randy D. ;

Horning, Sandra J. .

BRITISH JOURNAL OF HAEMATOLOGY, 2010, 151 (02) :143-151

[2] Revised response criteria for malignant lymphoma [J].

Cheson, Bruce D. ;

Pfistner, Beate ;

Juweid, Malik E. ;

Gascoyne, Randy D. ;

Specht, Lena ;

Horning, Sandra J. ;

Coiffier, Bertrand ;

Fisher, Richard I. ;

Hagenbeek, Anton ;

Zucca, Emanuele ;

Rosen, Steven T. ;

Stroobants, Sigrid ;

Lister, T. Andrew ;

Hoppe, Richard T. ;

Dreyling, Martin ;

Tobinai, Kensei ;

Vose, Julie M. ;

Connors, Joseph M. ;

Federico, Massimo ;

Diehl, Volker .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (05) :579-586

[3] Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte [J].

Coiffier, Bertrand ;

Thieblemont, Catherine ;

Van Den Neste, Eric ;

Lepeu, Gerard ;

Plantier, Isabelle ;

Castaigne, Sylvie ;

Lefort, Sophie ;

Marit, Gerald ;

Macro, Margaret ;

Sebban, Catherine ;

Belhadj, Karim ;

Bordessoule, Dominique ;

Ferme, Christophe ;

Tilly, Herve .

BLOOD, 2010, 116 (12) :2040-2045

[4]

COX DR, 1972, J R STAT SOC B, V34, P187

[5] THE IMPORTANCE OF DOSE INTENSITY IN CHEMOTHERAPY OF METASTATIC BREAST-CANCER [J].

HRYNIUK, W ;

BUSH, H .

JOURNAL OF CLINICAL ONCOLOGY, 1984, 2 (11) :1281-1288

[6] Investigation of the freely available easy-to-use software 'EZR' for medical statistics [J].

Kanda, Y. .

BONE MARROW TRANSPLANTATION, 2013, 48 (03) :452-458

[7] NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].

KAPLAN, EL ;

MEIER, P .

JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481

[8]

MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163

[9] Rituximab plus 70% cyclophosphamide, doxorubicin, vincristine and prednisone for Japanese patients with diffuse large B-cell lymphoma aged 70 years and older [J].

Meguro, Akiko ;

Ozaki, Katsutoshi ;

Sato, Kazuya ;

Oh, Iekuni ;

Fujiwara, Shinichiro ;

Hosonuma, Rie ;

Sasazaki, Miyuki ;

Kikuchi, Yuji ;

Hirata, Yuji ;

Yamamoto, Chihiro ;

Uesawa, Mitsuyo ;

Kobayashi, Hiroyuki ;

Matsu, Haruko ;

Okabe, Hiroshi ;

Uehara, Eisuke ;

Nishikawa, Akinori ;

Tatara, Raine ;

Hatano, Kaoru ;

Yamamoto, Chizuru ;

Matsuyama, Tomohiro ;

Toshima, Masaki ;

Ueda, Masuzu ;

Ohmine, Ken ;

Suzuki, Takahiro ;

Mori, Masaki ;

Nagai, Tadashi ;

Muroi, Kazuo ;

Ozawa, Keiya .

LEUKEMIA & LYMPHOMA, 2012, 53 (01) :43-49

[10] Activity and Safety of Dose-Adjusted Infusional Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Chemotherapy With Rituximab in Very Elderly Patients With Poor-Prognostic Untreated Diffuse Large B-Cell Non-Hodgkin Lymphoma [J].

Musolino, Antonino ;

Boggiani, Daniela ;

Panebianco, Michele ;

Vasini, Giovanna ;

Salvagni, Stefania ;

Franciosi, Vittorio ;

Ardizzoni, Andrea .

CANCER, 2011, 117 (05) :964-973

← 1 2 →